Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Oncology
352 Articles Available
1
15
Can't find what you're looking for? Try our
advanced search
.
Natural Killer T cells
Combating Cancer and Other Diseases with Supercharged NKT Cells
PAP-Q4-20-CL-005
Fast Track
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
PR-M11-20-012
Cancer Vaccine
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
PR-M11-20-009
Award
RefleXion and Sofinnova Partners Recognized with Salus Excellence Award at the Convergence in Oncology Summit
PR-M09-20-29
FDA Approval
FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
PR-M08-20-NI-11
Leadership
Premier Research Adds to Diverse Team of Oncology Experts
PR-M08-20-NI-12
Collaboration
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
PR-M07-20-NI-023
Nice Insight Overview
Drug Approval Trends: Significant Acceleration in Recent Years
PAP-Q2-20-NI-001
Molecules
Molecules that Changed Medicine
PAP-Q2-20-NI-002
Antibody–Drug Conjugates
Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life
PAP-Q2-20-CL-012
Clinical Trials
FDA Announces First of Its Kind Pilot Program to Communicate Patient Reported Outcomes from Cancer Clinical Trials
PR-M06-20-NI-032
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
PR-M06-20-NI-020
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
PR-M06-20-NI-019
Collaboration
AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics
PR-M06-20-NI-005
Oncology
AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials
PR-M05-20-NI-044
Cancer Treatment
HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment
PR-M05-20-NI-024
FDA Approval
Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14
PR-M05-20-NI-011
FDA Approval
Roche Receives FDA Approval for Cobas HPV Test to Identify Women at Risk for Cervical Cancer
PR-M04-20-NI-031
FDA Approval
Seattle Genetics Announces FDA Approval of TUKYSA for Breast Cancer
PR-M04-20-NI-028
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
PR-M03-20-NI-036
RNA Biomarkers
RNA Biomarkers for Early Lung Cancer Diagnosis
PAP-Q1-20-CL-014
In Conversation
In Conversation: NantKwest — Harnessing Natural Killer Cells to Treat Cancer
PAP-Q1-20-CL-016
Cancer Screening
Innovating to Increase Adherence for Colon Cancer Screening
PAP-Q1-20-CL-018
Digital Therapeutics
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
PR-M03-20-NI-011
1
15
»
